Cargando…

Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor

Background: Esophagogastric junction tumor (EGJ) is a rare but fatal disease with a rapid rising incidence worldwide in the late 20 years, and it lacks a convenient and safe method for diagnosis. The present study aimed to evaluate the potential of serum CYR61 as a biomarker for the diagnosis of EGJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Ling-Yu, Zhou, Jian-Yuan, Zhao, Yi-Xuan, Ou, Yan-Ting, Yang, Tian, Peng, Yu-Hui, Fang, Wang-Kai, Xu, Yi-Wei, Xie, Jian-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217984/
https://www.ncbi.nlm.nih.gov/pubmed/34085702
http://dx.doi.org/10.1042/BSR20204117
_version_ 1783710701194313728
author Chu, Ling-Yu
Zhou, Jian-Yuan
Zhao, Yi-Xuan
Ou, Yan-Ting
Yang, Tian
Peng, Yu-Hui
Fang, Wang-Kai
Xu, Yi-Wei
Xie, Jian-Jun
author_facet Chu, Ling-Yu
Zhou, Jian-Yuan
Zhao, Yi-Xuan
Ou, Yan-Ting
Yang, Tian
Peng, Yu-Hui
Fang, Wang-Kai
Xu, Yi-Wei
Xie, Jian-Jun
author_sort Chu, Ling-Yu
collection PubMed
description Background: Esophagogastric junction tumor (EGJ) is a rare but fatal disease with a rapid rising incidence worldwide in the late 20 years, and it lacks a convenient and safe method for diagnosis. The present study aimed to evaluate the potential of serum CYR61 as a biomarker for the diagnosis of EGJ tumor. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to estimate CYR61 levels in sera of 152 EGJ tumor patients and 137 normal controls. Receiver operating characteristics (ROC) was carried out to evaluate the diagnostic accuracy. The Mann–Whitney’s U test was used to compare the difference of serum levels of CYR61 between groups. And chi-square tests were employed to estimate the correlation of the positive rate of serum CYR61 between/among subgroups. Results: Serum CYR61 levels were statistically lower in EGJ tumor and early-stage EGJ tumor patients than those in normal controls (P<0.0001). The sensitivity, specificity and the area under the curve (AUC) of this biomarker in EGJ tumor were 88.2%, 43.8% and 0.691, respectively, and those for early stage of EGJ tumor were 80.0%, 66.4% and 0.722, respectively. Analyses showed that there was no correlation between the clinical data and the levels of CYR61 (P>0.05). Conclusion: The present study showed that CYR61 might be a potential biomarker to assist the diagnosis of EGJ tumor.
format Online
Article
Text
id pubmed-8217984
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-82179842021-07-02 Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor Chu, Ling-Yu Zhou, Jian-Yuan Zhao, Yi-Xuan Ou, Yan-Ting Yang, Tian Peng, Yu-Hui Fang, Wang-Kai Xu, Yi-Wei Xie, Jian-Jun Biosci Rep Cancer Background: Esophagogastric junction tumor (EGJ) is a rare but fatal disease with a rapid rising incidence worldwide in the late 20 years, and it lacks a convenient and safe method for diagnosis. The present study aimed to evaluate the potential of serum CYR61 as a biomarker for the diagnosis of EGJ tumor. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to estimate CYR61 levels in sera of 152 EGJ tumor patients and 137 normal controls. Receiver operating characteristics (ROC) was carried out to evaluate the diagnostic accuracy. The Mann–Whitney’s U test was used to compare the difference of serum levels of CYR61 between groups. And chi-square tests were employed to estimate the correlation of the positive rate of serum CYR61 between/among subgroups. Results: Serum CYR61 levels were statistically lower in EGJ tumor and early-stage EGJ tumor patients than those in normal controls (P<0.0001). The sensitivity, specificity and the area under the curve (AUC) of this biomarker in EGJ tumor were 88.2%, 43.8% and 0.691, respectively, and those for early stage of EGJ tumor were 80.0%, 66.4% and 0.722, respectively. Analyses showed that there was no correlation between the clinical data and the levels of CYR61 (P>0.05). Conclusion: The present study showed that CYR61 might be a potential biomarker to assist the diagnosis of EGJ tumor. Portland Press Ltd. 2021-06-18 /pmc/articles/PMC8217984/ /pubmed/34085702 http://dx.doi.org/10.1042/BSR20204117 Text en © 2021 The Author(s). https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Cancer
Chu, Ling-Yu
Zhou, Jian-Yuan
Zhao, Yi-Xuan
Ou, Yan-Ting
Yang, Tian
Peng, Yu-Hui
Fang, Wang-Kai
Xu, Yi-Wei
Xie, Jian-Jun
Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
title Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
title_full Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
title_fullStr Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
title_full_unstemmed Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
title_short Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
title_sort serum cyr61 as a potential biomarker for the diagnosis of esophagogastric junction tumor
topic Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217984/
https://www.ncbi.nlm.nih.gov/pubmed/34085702
http://dx.doi.org/10.1042/BSR20204117
work_keys_str_mv AT chulingyu serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT zhoujianyuan serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT zhaoyixuan serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT ouyanting serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT yangtian serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT pengyuhui serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT fangwangkai serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT xuyiwei serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor
AT xiejianjun serumcyr61asapotentialbiomarkerforthediagnosisofesophagogastricjunctiontumor